Security
Syndax Pharmaceuticals, Inc. Common Stock · SNDX
SNDXNASDAQCommon stockCurrentCIK 1395937Updated Nov 3, 2026
SNDX price & chart
Loading TradingView…
NASDAQ:SNDX on TradingView ↗About the company
Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company advancing innovative cancer therapies. Highlights of the Company's pipeline include Revuforj® (revumenib), an FDA-approved menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment. For more information, please visit www.syndax.com/ or follow the Company on X and LinkedIn.
In the news
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) ↗
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) News provided by Syndax Pharmaceuticals, Inc. Feb 04, 2025, 16:05 ET Share this article Share to X Share this article Share to X WALTHAM, Mass. , Feb. 4, 2025 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX ) ↗
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) News provided by Syndax Pharmaceuticals, Inc. Jan 03, 2025, 16:05 ET Share this article Share to X Share this article Share to X WALTHAM, Mass. , Jan. 3, 2025 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX ) ↗
Seeking Alpha
Syndax anticipates Revuforj could exceed $2B in U.S. peak annual net revenue as post-transplant maintenance builds ↗
Syndax Pharmaceuticals, Inc. (SNDX) Q3 2026 Earnings Call Transcript ↗
The AI Bubble Ran Into Reality Last Week ↗
SEC disclosures
Syndax Pharmaceuticals Inc files 8-K: Material Event ↗
Recent filings
10-Q filing
Results of Operations and Financial Condition · Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Items 2.02, 5.02, 9.01
4 filing
144 filing
10-Q filing
Show 5 more recent filings
Results of Operations and Financial Condition
Items 2.02, 9.01
Other Events
Items 8.01, 9.01
144 filing
Entry into a Material Definitive Agreement · Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement · Unregistered Sales of Equity Securities
Items 1.01, 2.03, 3.02, 9.01
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Submission of Matters to a Vote of Security Holders
Items 5.02, 5.07, 9.01
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 551,792,000Source | 425,811,000Source | 703,652,000Source | 596,149,000Source | 476,947,000Source | 472,668,000Source | 640,707,000Source | 543,028,000Source | 529,706,000Source | 724,816,000Source | 612,880,000Source | 497,236,000Source |
| Property, Plant and Equipment, NetUSD | 128,000Source | 0Source | 212,000Source | 0Source | 2,000Source | 177,000Source | 0Source | 5,000Source | 181,000Source | 0Source | 8,000Source | 20,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 116,808,000Source | 133,019,000Source | 336,477,000Source | 108,636,000Source | 105,396,000Source | 130,893,000Source | 153,993,000Source | 114,615,000Source | 134,930,000Source | 154,083,000Source | 295,394,000Source | 74,356,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | — | — | — | — | — | — | — | — | 37,996,000Source | 7,602,000Source | — | — |
| Inventory, NetUSD | 25,000,000Source | — | 33,164,000Source | 17,696,000Source | — | 34,948,000Source | 4,664,000Source | — | 32,754,000Source | 366,000Source | — | — |
| Assets, CurrentUSD | 529,830,000Source | 414,809,000Source | 675,039,000Source | 531,676,000Source | 446,056,000Source | 471,177,000Source | 548,751,000Source | 453,899,000Source | 528,081,000Source | 603,057,000Source | 580,876,000Source | 489,786,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 9,517,000Source | 4,907,000Source | 17,480,000Source | 9,875,000Source | 4,207,000Source | 16,100,000Source | 8,462,000Source | 4,665,000Source | 13,496,000Source | 8,541,000Source | 3,293,000Source | 1,915,000Source |
| Operating Lease, Right-of-Use AssetUSD | 1,471,000Source | 756,000Source | 1,082,000Source | 1,629,000Source | 1,000,000Source | 1,212,000Source | 1,801,000Source | 1,243,000Source | 1,342,000Source | 2,022,000Source | 1,487,000Source | 1,039,000Source |
| Other Assets, NoncurrentUSD | — | 0Source | — | — | 156,000Source | — | — | 248,000Source | — | 0Source | 463,000Source | 807,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 436,362,000Source | 59,379,000Source | 688,553,000Source | 438,725,000Source | 42,609,000Source | 431,046,000Source | 425,648,000Source | 51,139,000Source | 465,076,000Source | 436,692,000Source | 58,684,000Source | 29,787,000Source |
| Stockholders’ equity: | ||||||||||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | — | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source |
| Common Stock, Value, IssuedUSD | 9,000Source | 9,000Source | 9,000Source | 9,000Source | 9,000Source | 9,000Source | 9,000Source | 8,000Source | 9,000Source | 9,000Source | 8,000Source | 7,000Source |
| Retained Earnings (Accumulated Deficit)USD | -1,438,566,000Source | -1,126,989,000Source | -1,598,616,000Source | -1,377,851,000Source | -1,042,863,000Source | -1,549,253,000Source | -1,306,004,000Source | -974,800,000Source | -1,506,580,000Source | -1,221,158,000Source | -902,400,000Source | -693,040,000Source |
| Stockholders' Equity Attributable to ParentUSD | 115,430,000Source | 366,432,000Source | 15,099,000Source | 157,424,000Source | 434,338,000Source | 41,622,000Source | 215,059,000Source | 491,889,000Source | 64,630,000Source | 288,124,000Source | 554,196,000Source | 467,449,000Source |
| Additional Paid in Capital, Common StockUSD | 1,553,462,000Source | 1,493,041,000Source | 1,613,846,000Source | 1,534,981,000Source | 1,478,009,000Source | 1,590,855,000Source | 1,520,527,000Source | 1,467,437,000Source | 1,570,749,000Source | 1,509,110,000Source | 1,456,370,000Source | 1,161,288,000Source |
| Liabilities and EquityUSD | 551,792,000Source | 425,811,000Source | 703,652,000Source | 596,149,000Source | 476,947,000Source | 472,668,000Source | 640,707,000Source | 543,028,000Source | 529,706,000Source | 724,816,000Source | 612,880,000Source | 497,236,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 114,187,000Source | 59,377,000Source | 99,677,000Source | 112,987,000Source | 42,472,000Source | 86,174,000Source | 94,551,000Source | 50,805,000Source | 120,116,000Source | 103,549,000Source | 58,096,000Source | 29,065,000Source |
| Operating Lease, Liability, CurrentUSD | 329,000Source | 842,000Source | 506,000Source | 344,000Source | 981,000Source | 487,000Source | 377,000Source | 1,042,000Source | 470,000Source | 471,000Source | 1,035,000Source | 434,000Source |
| Accounts Payable, CurrentUSD | 13,826,000Source | 4,898,000Source | 4,874,000Source | 17,353,000Source | 11,568,000Source | 10,843,000Source | 10,047,000Source | 8,809,000Source | 16,580,000Source | 11,626,000Source | 9,961,000Source | 4,350,000Source |
| Operating Lease, Liability, NoncurrentUSD | — | 0Source | — | — | 133,000Source | — | — | 327,000Source | — | 1,578,000Source | 578,000Source | 709,000Source |
| Additional Financial Items | ||||||||||||
| AOCI, Debt Securities, Available-for-sale, Adjustment, after TaxUSD | 525,000Source | 371,000Source | -140,000Source | 285,000Source | -817,000Source | 11,000Source | 527,000Source | -756,000Source | 452,000Source | 163,000Source | 218,000Source | -806,000Source |
| Long-term Debt, Current MaturitiesUSD | 327,075,000Source | — | 350,000,000Source | 330,565,000Source | — | 350,000,000Source | 335,852,000Source | — | 350,000,000Source | 337,884,000Source | — | — |
| Short-term InvestmentsUSD | 319,171,000Source | 256,588,000Source | 211,383,000Source | 346,597,000Source | 319,701,000Source | 221,171,000Source | 358,204,000Source | 319,963,000Source | 259,140,000Source | 418,801,000Source | 275,304,000Source | 401,446,000Source |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | -42,673,000Source | -84,846,000Source | -285,422,000Source | -318,758,000Source | -209,360,000Source | -149,338,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 12,054,000Source | 10,380,000Source | 47,503,000Source | 43,026,000Source | 30,951,000Source | 16,019,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | -120,000Source | 8,120,000Source | 30,394,000Source | 7,602,000Source | — | — |
| Increase (Decrease) in InventoriesUSD | — | — | — | — | — | — | 2,060,000Source | 4,191,000Source | 32,091,000Source | 366,000Source | — | — |
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | -5,737,000Source | -1,579,000Source | 4,954,000Source | 1,665,000Source | 5,611,000Source | -1,319,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -50,345,000Source | -95,162,000Source | -322,980,000Source | -274,903,000Source | -160,601,000Source | -133,675,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | 38,390,000Source | 94,142,000Source | 290,036,000Source | -219,775,000Source | 117,609,000Source | -186,188,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | — | — | 187,000Source | — | 0Source | 0Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 7,918,000Source | 930,000Source | 13,676,000Source | 353,367,000Source | 264,132,000Source | 172,254,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | -4,037,000Source | -90,000Source | -19,268,000Source | -141,311,000Source | 221,140,000Source | -147,609,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | — | — | — | 0Source | 0Source | 2,059,000Source |
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | — | — | 150Source | — | — | — |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 12,082,000Source | 11,934,000Source | 14,014,000Source | 13,787,000Source | 12,053,000Source | 10,380,000Source | 47,503,000Source | 43,026,000Source | 30,951,000Source | 16,019,000Source |
| Amortization of Debt Issuance CostsUSD | — | — | — | — | — | — | 56,000Source | 112,000Source | 228,000Source | 30,000Source | — | — |
| Debt Securities, Available-for-sale, Realized Gain (Loss)USD | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source |
| DepreciationUSD | — | — | — | — | 5,000,000Source | 0Source | 4,000,000Source | 0Source | 6,000,000Source | 8,000,000Source | 12,000,000Source | 33,000,000Source |
| Derivative, Gain (Loss) on Derivative, NetUSD | — | — | — | — | — | — | — | — | — | 0Source | 0Source | 187,000Source |
| General and Administrative ExpenseUSD | — | — | 44,917,000Source | 31,106,000Source | 41,539,000Source | 43,805,000Source | 37,588,000Source | 41,031,000Source | — | — | — | 33,258,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | 0Source | 0Source | 433,000Source | — | — | — |
| InterestExpenseNonoperatingUSD | — | — | 0Source | 23,000Source | 2,000Source | 4,000Source | 0Source | 2,000Source | 6,000Source | 4,929,000Source | — | — |
| Investment Income, InterestUSD | — | — | 5,269,000Source | 5,442,000Source | 3,746,000Source | 5,950,000Source | 3,561,000Source | 7,183,000Source | 22,730,000Source | 26,090,000Source | 21,163,000Source | 5,872,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -60,715,000Source | -84,126,000Source | -49,363,000Source | -71,847,000Source | -42,673,000Source | -84,846,000Source | -285,422,000Source | -318,758,000Source | -209,360,000Source | -149,338,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -60,715,000Source | -84,126,000Source | -49,363,000Source | -71,847,000Source | -42,673,000Source | -84,846,000Source | -285,422,000Source | -318,758,000Source | -209,360,000Source | -149,338,000Source |
| Nonoperating Income (Expense)USD | — | — | -3,289,000Source | 5,451,000Source | -9,368,000Source | -2,494,000Source | -8,471,000Source | -1,089,000Source | -12,338,000Source | 20,914,000Source | 20,594,000Source | 2,419,000Source |
| Operating ExpensesUSD | — | — | 103,297,000Source | 102,077,000Source | 112,783,000Source | 107,311,000Source | 99,066,000Source | 103,799,000Source | 445,436,000Source | 363,352,000Source | 229,954,000Source | 151,757,000Source |
| Operating Lease, ExpenseUSD | — | — | — | — | — | — | — | — | 900,000Source | 1,100,000Source | 743,000Source | 440,000Source |
| Other Nonoperating Income (Expense)USD | — | — | -275,000Source | 32,000Source | -438,000Source | -586,000Source | -186,000Source | -221,000Source | -1,283,000Source | -247,000Source | -361,000Source | -316,000Source |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | 7,460,000Source | 385,000Source | 12,138,000Source | 8,000,000Source | 5,128,000Source | 11,459,000Source |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 45,871,000Source | 12,500,000Source | 72,788,000Source | 37,958,000Source | 64,864,000Source | 20,042,000Source | 172,352,000Source | 23,680,000Source | 0Source | — |
| Selling, General and Administrative ExpenseUSD | — | — | — | — | — | — | — | — | 179,682,000Source | 120,879,000Source | 66,922,000Source | — |
| Operating Income (Loss)USD | — | — | -57,426,000Source | -89,577,000Source | -39,995,000Source | -69,353,000Source | -34,202,000Source | -83,757,000Source | -273,084,000Source | -339,672,000Source | -229,954,000Source | -151,757,000Source |
| Other Nonoperating Income (Expense)USD | — | — | -275,000Source | 32,000Source | -438,000Source | -586,000Source | -186,000Source | -221,000Source | -1,283,000Source | -247,000Source | -361,000Source | -316,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | 0Source | 0Source | 433,000Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -60,715,000Source | -84,126,000Source | -49,363,000Source | -71,847,000Source | -42,673,000Source | -84,846,000Source | -285,422,000Source | -318,758,000Source | -209,360,000Source | -149,338,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.7Source | -0.98Source | -0.55Source | -0.83Source | -0.48Source | -0.98Source | -3.29Source | -3.72Source | -2.98Source | -2.46Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.7Source | -0.98Source | -0.55Source | -0.83Source | -0.48Source | -0.98Source | -3.29Source | -3.72Source | -2.98Source | -2.46Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 86,620,992Source | 85,433,569Source | 88,991,317Source | 86,337,237Source | 88,255,636Source | 86,171,889Source | 86,625,610Source | 85,622,065Source | 70,370,519Source | 60,760,906Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 86,620,992Source | 85,433,569Source | 88,991,317Source | 86,337,237Source | 88,255,636Source | 86,171,889Source | 86,625,610Source | 85,622,065Source | 70,370,519Source | 60,760,906Source |
| Interest Expense (non-operating)USD | — | — | 0Source | 23,000Source | 2,000Source | 4,000Source | 0Source | 2,000Source | 6,000Source | 4,929,000Source | — | — |
| Additional Financial Items | ||||||||||||
| General and Administrative ExpenseUSD | — | — | 44,917,000Source | 31,106,000Source | 41,539,000Source | 43,805,000Source | 37,588,000Source | 41,031,000Source | — | — | — | 33,258,000Source |
| Interest ExpenseUSD | — | — | — | — | — | — | — | — | — | — | 208,000Source | 3,137,000Source |
| Investment Income, InterestUSD | — | — | 5,269,000Source | 5,442,000Source | 3,746,000Source | 5,950,000Source | 3,561,000Source | 7,183,000Source | 22,730,000Source | 26,090,000Source | 21,163,000Source | 5,872,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -60,715,000Source | -84,126,000Source | -49,363,000Source | -71,847,000Source | -42,673,000Source | -84,846,000Source | -285,422,000Source | -318,758,000Source | -209,360,000Source | -149,338,000Source |
| Nonoperating Income (Expense)USD | — | — | -3,289,000Source | 5,451,000Source | -9,368,000Source | -2,494,000Source | -8,471,000Source | -1,089,000Source | -12,338,000Source | 20,914,000Source | 20,594,000Source | 2,419,000Source |
| Operating ExpensesUSD | — | — | 103,297,000Source | 102,077,000Source | 112,783,000Source | 107,311,000Source | 99,066,000Source | 103,799,000Source | 445,436,000Source | 363,352,000Source | 229,954,000Source | 151,757,000Source |
| Operating Lease, ExpenseUSD | — | — | — | — | — | — | — | — | 900,000Source | 1,100,000Source | 743,000Source | 440,000Source |
| Research and Development ExpenseUSD | — | — | 56,280,000Source | 70,971,000Source | 68,036,000Source | 62,227,000Source | 58,845,000Source | 61,636,000Source | 258,784,000Source | 241,647,000Source | 163,032,000Source | 118,499,000Source |
Filing attachments
sndx-ex99_1.htm · 8-K · 2026-11-02
Exhibit 99.1 Syndax Reports Third Quarter 2026 Financial Results and Provides Business Update • Total revenue of $83.3 million in 3Q26, an 82% year-over-year increase - Revuforj® (revumenib) net revenue of $60.7 million in 3Q26, a 90% y/y increase, underscores leadership in R/R NPM1m and KMT2Ar acute leukemia; 20% q/q growth in new patients • Niktimvo™ (axatilimab-csfr) net revenue of $67.4 million in 3Q26, a 47% y/y increase, resulting in Syndax collaboration revenue of $22.6 million - • N…
Read attachment ↗sndx-ex99_2.htm · 8-K · 2026-11-02
November 2, 2026 Third Quarter 2026 Financial Results and Business Update Exhibit 99.2 Forward-looking statements disclosure This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate" and similar expressions (as well as other words or expressions referencing future events, progress, timing or circumstances) are intended to identify forward-looking statements. All st…
Read attachment ↗sndx-ex99_1.htm · 8-K · 2026-08-04
EX-99.1 2 sndx-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Syndax Reports Second Quarter 2026 Financial Results and Provides Business Update • Total revenue of $73 million in 2Q26, a 92% year-over-year increase - • Revuforj® (revumenib) net revenue of $54.7 million in 2Q26, a 91% year-over-year increase - - • Niktimvo™ (axatilimab-csfr) net revenue of $60.3 million in 2Q26, a 67% year-over-year increase, resulting in Syndax collaboration revenue of $18.1 million - • Expanded pipeline with …
Read attachment ↗sndx-ex99_2.htm · 8-K · 2026-08-04
EX-99.2 3 sndx-ex99_2.htm EX-99.2 Second Quarter 2026 Financial Results and Business Update August 4, 2026 Exhibit 99.2 Forward-looking statements disclosure This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate" and similar expressions (as well as other words or expressions referencing future events, progress, timing or circumstances) are intended to identi…
Read attachment ↗sndx-ex99_1.htm · 8-K · 2026-07-14
EX-99.1 2 sndx-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Syndax to Highlight Late-Stage Programs and Unveil New Pipeline Assets at R&D Event - Expands pipeline with SNDX-4321, a novel, mutant-selective, allosteric EGFR inhibitor designed to address NSCLC patient populations with significant unmet needs - - SNDX-62122, a next-generation menin inhibitor, selected for development in MF, building on compelling preclinical results observed with revumenib in MF - - SNDX-62122 is the first candi…
Read attachment ↗sndx-ex99_2.htm · 8-K · 2026-07-14
EX-99.2 3 sndx-ex99_2.htm EX-99.2 Syndax 2026 R&D Event July 14, 2026 Exhibit 99.2 Forward-looking statements disclosure This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate" and similar expressions (as well as other words or expressions referencing future events, progress, timing or circumstances) are intended to identify forward-looking statements. All st…
Read attachment ↗